66 results about "Plaque area" patented technology

The invention relates to the field of cardiovascular medicine, and discloses a coronary artery vulnerable plaque detection and analysis system which comprises a data collection module used for collecting multi-mode imaging data of a coronary artery and identifying the blood vessel structure and the blood vessel type of the coronary artery, and a plaque area identification module used for positioning the branch opening position of the coronary artery and identifying the blood vessel structure and the blood vessel type of the coronary artery. Multi-class plaques of coronary arteries are separated out; the plaque classification detection module is used for extracting structural features of multiple categories of plaques, identifying vulnerable plaques and stable plaques in the coronary artery and setting a plaque classification detection system of the coronary artery; the vulnerable plaque evaluation module is used for constructing a coronary artery vulnerable plaque scoring mechanism according to the plaque vulnerability index, the plaque component and the radial wall strain value; and the result feedback module is used for generating a vulnerable plaque feedback result of the coronary artery in combination with the vulnerable plaque scoring mechanism and the plaque classification detection system. According to the invention, the accuracy of coronary artery vulnerable plaque detection can be improved.

The invention discloses a coronary artery vulnerable plaque identification method and device based on a multi-modal large model. The method comprises the following steps: acquiring a three-dimensional coronary artery CCTA image to be identified and an SCPR image to be identified; plaque mask information on the blood vessel is obtained; obtaining basic patch data; obtaining fluid mechanics data of each plaque area; obtaining clinical detection basic information; performing feature extraction and feature fusion on the original three-dimensional coronary artery CCTA image, the to-be-recognized SCPR image, the plaque mask information, the basic plaque data and the fluid mechanics data to obtain first fusion data; fusing the first fusion data with the clinical detection basic information to obtain second fusion data; obtaining a vulnerable plaque identification large model; and inputting the second fusion data into the vulnerable plaque identification large model to obtain an identification result. According to the method, the plaque features, the fluid mechanics features and the text features are fused, so that the problems of poor feature expression ability and low recognition performance of a traditional single image are solved.

The invention relates to the technical field of carotid artery stent simulation, and relates to a carotid artery stent simulation method and system based on a virtual intervention algorithm, and the method comprises the steps: obtaining first image information which comprises carotid artery image information; determining the stenosis degree of the carotid artery and the component index of each plaque area according to the first image information; constructing a virtual carotid artery blood vessel three-dimensional model according to the stenosis degree of the carotid artery and the component index of each plaque region; obtaining a preset virtual support three-dimensional model; the contact between a preset virtual stent three-dimensional model and a virtual carotid artery blood vessel three-dimensional model is analyzed through a mechanical analysis method, a simulation result is obtained, and the simulation result comprises the unfolded form of the stent in the body of the patient; the dynamic constraint change between the nodes and the mutual influence between the blood vessel stress and the stent expansion can be accurately captured, and the simulation precision is greatly improved, so that the operation safety is improved.

The invention belongs to the field of active peptides, and particularly relates to a selenium-containing composition and application thereof in coronary atherosclerosis, the selenium-containing composition comprises a selenium peptide chelate, and the selenium peptide chelate is prepared by chelating almond active peptide as shown in SEQ ID NO: 1 and inorganic selenium; the selenium peptide chelate has the effects of remarkably reducing the concentrations of TC, TG, HDL-C and LDL-C in serum, having high antioxidant and anti-inflammatory activity and reducing the area proportion of atherosclerotic plaques, and can be used for treating and / or preventing coronary atherosclerosis diseases.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

A method for evaluating plaque load based on OCT images is characterized in that fitting is carried out through the far end and the near end of a blood vessel lumen of the OCT images, a reference lumen at a plaque is fitted out, and then a middle membrane area and a plaque area can be calculated, so that the plaque load condition is evaluated; the imaging length of the intravascular OCT is usually 50-80 mm, the intravascular OCT generally comprises a far end, a lesion part and a near end, and the image of the near end is close to a coronary artery opening and has a larger diameter; the distal end is far away from the coronary opening, the diameter is relatively small, and the diameter of the healthy blood vessel from the proximal end to the distal end generally decreases linearly; when a blood vessel has plaque, the space-occupying effect causes the diameter of the lumen of the blood vessel at the plaque to become smaller. The invention can acquire the real plaque load through the conventional OCT image, provides basis for diagnosis and is beneficial to expanding the scope and quality of OCT diagnosis.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia. The traditional Chinese medicine composition comprises the following components: ginseng, lucid ganoderma, safflower, musk, calculus bovis, bear gall, pearl, venenum bufonis, radix aconiti carmichaeli and borneol. According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compatibility of all the components, at least one of indexes such as aorta plaque area, vasomotor inner diameter difference, intima-media thickness, blood fat level, homocysteine content and the like in atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia can be effectively improved; the symptoms of atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia are relieved from multiple aspects, and the progress of the disease course is blocked. The traditional Chinese medicine composition is controllable in quality, convenient for standardized production, safe and reliable in prescription and free of toxic and side effects on human bodies.

The invention discloses application of ilicin K in preparation of an anti-atherosclerosis medicine, and belongs to the technical field of biological medicines. Tests find that the ilicin K can effectively reduce CD72hi macrophage infiltration in plaque lesions, inhibit inflammatory response, improve lipid metabolism, reduce plaque area and improve plaque stability, has remarkable advantages in the aspect of atherosclerosis resistance, and provides a new idea and choice for treatment and drug combination of atherosclerosis.

In the blood vessel projection visualization method and the program product provided by the invention, a first image of computed tomography angiography and a second image of digital subtraction angiography in a target area are acquired, a blood vessel path and a plaque area in the first image are determined, and a grid structure of the blood vessel path is constructed; and according to the position relationship between the grid structure and the plaque region in the first image, obtaining the shielding relationship between the grid structure and the plaque region, and based on the shielding relationship, rendering the grid structure and the plaque region in the second image to obtain a fused image. By constructing the grid structure of the blood vessel path and rendering the grid structure and the plaque region in the second image based on the shielding relationship between the grid structure and the plaque region to obtain the fused image, the blood vessel stenosis degree, the blood vessel dilation degree and the plaque position are displayed, and the blood vessel stenosis degree and the blood vessel dilation degree are displayed at the same time. And the position relationship between the grid structure and the plaque region in the mapping direction of the second image is intuitively reflected.

The invention discloses a self-adaptive intervention type single-array-element photoacoustic endoscopic imaging near-field noise removal method based on a spatial domain and morphological characteristics. The method comprises the following steps that 1, original data of photoacoustic endoscopic imaging are obtained; step 2, adaptively generating a patch mask area; 3, preprocessing the image in a frequency domain; step 4, executing strip interference detection based on adaptive spatial domain filtering on the non-plaque region to obtain a spatial domain noise mask; step 5, screening strip-shaped noise areas; step 6, performing interpolation restoration on the noise area; 7, calculating the convergence degree and the noise level in the iteration process; and step 8, outputting a final result after polar coordinate transformation. The intrusive single-array-element photoacoustic endoscopic imaging method can effectively inhibit strip-shaped interference signals occurring in intrusive single-array-element photoacoustic endoscopic imaging and reduce the covering influence of background noise on target signals, so that the imaging quality of a near-end area is improved, and the structural definition and contrast ratio of overall imaging are remarkably optimized.

The invention provides an identification method for coronary artery vulnerable plaques, a storage medium and electronic equipment, and relates to the technical field of biomedical engineering.The identification method comprises the steps that blood vessel segmentation is conducted on a CCTA image; for each blood vessel segment obtained by segmentation, the following processing steps are performed: straightening curved surface reconstruction is performed to generate an SCPR image, and plaque detection is performed based on the SCPR image to position a first plaque area; analyzing the PCAT region corresponding to the blood vessel segment, and determining a CT value distribution diagram in spatial registration with the first plaque region; performing dynamic re-segmentation processing on the first plaque region according to the CT value distribution diagram to determine a second plaque region; and converting an image corresponding to the second plaque region, and inputting the converted image into the trained model to obtain an identification result. In the application, on the basis of the existing form-based vulnerable plaque identification, PCAT analysis is introduced to carry out joint identification, so that improvement of the overall identification performance is facilitated.

The invention discloses a solar cell and a manufacturing method thereof, and a photovoltaic module, relates to the technical field of photovoltaic, and is used for reducing the risk that the surface of a semiconductor substrate and a surface passivation layer are scratched, facilitating the improvement of the passivation effect of the surface passivation layer on the semiconductor substrate, and further facilitating the improvement of the conversion efficiency of the solar cell. The solar cell comprises a semiconductor substrate and a surface passivation layer. The semiconductor substrate includes a textured topography region. Suede structures are densely distributed in the suede morphology area. And the surface passivation layer is directly arranged on the suede morphology area. Wherein the suede morphology area comprises a non-plaque area and a plurality of plaque areas dispersed in the non-plaque area. In the thickness direction of the semiconductor substrate, the height of the plaque region is smaller than that of the non-plaque region. The photovoltaic module comprises the solar cell. The manufacturing method of the solar cell is used for manufacturing the solar cell.

A medical image processing apparatus includes a catheter including a sensor and insertable into a blood vessel, a display, and a processor configured to: control the catheter to acquire tomographic images of the vessel, input the images into a model and acquire information indicating a condition of a part of the blood vessel, generate a histogram of a plaque area ratio in the vessel, acquire a length of a stent to be placed or a lesion to be treated, calculate a threshold for the ratio using the first histogram and the length, generate a graph indicating the ratio at each part of the blood vessel, and control the display to display the graph and the threshold in an overlapping manner.

The invention discloses a preparation method of ginsenoside microvesicles and application of the ginsenoside microvesicles in targeted local treatment of atherosclerotic plaques through combination of the ginsenoside microvesicles and ultrasound, the ginsenoside microvesicles Rb3NPs (at) MBs prepared through the preparation method are evenly dispersed and consistent in size, and through combination of the ginsenoside microvesicles and the ultrasound, the effect of treating atherosclerotic plaques is achieved. The method is applied to targeted local treatment of atherosclerotic plaque, the plaque area is reduced by 41.84% relative to a model group, and the combined method effectively reduces atherosclerotic plaque at the aortic arch of a targeted mouse.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The invention discloses an MKP7 targeted bionic nanoparticle preparation as well as a preparation method and application thereof. The MKP7 targeted bionic nanoparticle preparation is a bionic nanoparticle siMKP7 (at) NP-M-pHLIP, wherein the bionic nanoparticle siMKP7 (at) NP-M-pHLIP is coated with a macrophage membrane modified by pHLIP and is loaded with siMKP7. According to the preparation, a PLGA-PEI copolymer is used as a carrier core to wrap siMKP7, an outer layer is coated with a macrophage membrane, the surface of the membrane is modified with pHLIP targeting peptide, and spherical nanoparticles with bionic camouflage and pH sensitive targeting delivery functions are constructed. In-vitro experiments show that the nanoparticles can be effectively ingested by macrophages, and macrophage lipid deposition induced by ox-LDL is remarkably inhibited; in-vivo experiments prove that the preparation can be delivered to atherosclerotic plaque parts in a targeted manner, and by inhibiting expression of MKP7 in macrophages, the carotid plaque area is effectively reduced, the serum inflammatory factor level is reduced, and the blood lipid metabolism is regulated, so that development of atherosclerosis is inhibited, and the curative effect of atherosclerosis is improved. A high-efficiency and low-toxicity nucleic acid drug delivery system is provided for treatment of atherosclerosis.

The invention discloses a system and a method for dynamically identifying vulnerable plaques of an intravascular ultrasonic image. According to the system, plaque evolution information of continuous IVUS image frames is extracted by constructing a feature extraction module based on a space-time convolutional neural network; combining limited OCT annotation data through a transfer learning model; the blood flow wall shear force and the inflammatory marker IL-6 are fused in a plaque rupture risk prediction matrix, and a new mathematical calculation model is provided to predict the plaque risk. The system supports real-time analysis in an interventional operation and automatically marks a high-risk plaque area, and the vulnerable plaque detection sensitivity can reach 94% or above. The hardware architecture comprises an image acquisition unit, a deep learning calculation module and a labeling interaction module; the software architecture comprises a plaque recognition engine, a shear force calculation module, a biological data fusion interface and the like. The system has the advantages of being easy and convenient to operate, high in real-time performance, high in accuracy and the like, and an efficient intraoperative plaque risk assessment tool is provided for interventional therapy.

The invention discloses an application of N1, N10-dicaffeoyl spermidine in preparation of a medicine for preventing and treating atherosclerosis. Belongs to the technical field of biological medicine. When the N1, N10-dicaffeoyl spermidine is administered to an experimental animal within the dosage range of 10-25 mg / kg, the area of ApoE- / -mouse atherosclerotic plaque induced by high homocysteine (HCY) can be remarkably reduced, meanwhile, the HCY level, the levels of four blood lipid items (TG, TC, LDL-C and HDL-C) and the levels of inflammatory factors such as IL-6, IL-1beta, TNF-alpha, MCP-1 and CRP in serum of the atherosclerotic mouse can be remarkably callback, and the N1, N10-dicaffeoyl spermidine can be used for treating atherosclerotic mice. All the results prove that the N1, N10-dicaffeoyl spermidine has the effect of improving the atherosclerosis and can be used for preventing and treating cardiovascular system diseases such as the atherosclerosis.

The invention provides a preparation method of a compound SS-23 and application of the compound SS-23 in preparation of drugs for preventing and / or treating atherosclerosis, and belongs to the technical field of chemical drugs. The compound SS-23 is a compound as shown in a formula I or a pharmaceutically acceptable salt thereof. The phenolic acid glyceride compound SS-23 is separated and purified from rhizoma sparganii, and the compound can play a role in preventing and / or treating atherosclerosis by adjusting the blood fat level, reducing the plaque area and improving the vascular function. The compound SS-23 has remarkable potential in the aspect of preventing and / or treating atherosclerosis, provides a new treatment strategy for clinic, and has a good application prospect. Formula I.

The invention relates to an ultrasonic carotid plaque type identification method and system and a storage medium, and the method comprises the following steps: respectively obtaining a neck ultrasonic image and carotid artery mechanical data before and after the extrusion of a carotid artery extrusion belt on a carotid artery, and carrying out the preprocessing; image reconstruction is carried out based on the neck ultrasonic image, probability statistics is carried out on a suspected plaque area in the reconstructed image, and the position and the form of a plaque are identified; the mechanical response of the carotid artery in the extrusion process is analyzed based on the carotid artery mechanical data; and inputting the identified position and form of the plaque and the mechanical response into the soft and hard plaque judgment model, and outputting a plaque type identification result. Compared with the prior art, the method has the advantages that an accurate carotid plaque type judgment result can be obtained, and the like.

The present application relates to the field of food, health care products and medicine, and specifically relates to a purslane oral composition for regulating blood lipid and resisting atherosclerosis, and a preparation method and application thereof. The present application takes purslane extract, galangal extract and borneol as core components, and realizes the synergistic effects of lipid regulation, anti-inflammation, reduction of plaque area, stabilization of vulnerable plaque, mild anti-thrombus and myocardial protection through scientific proportioning. The bioavailability is significantly improved by combining the tongue sublingual absorption of borneol and the mucosal penetration of galangal volatile oil. The composition has comprehensive targets, definite effects and good safety, and can be made into oral dosage forms such as buccal tablets, dripping pills and oral disintegrating tablets, and is suitable for daily oral care of cardiovascular sub-healthy people.

The application relates to the technical field of oral cavity equipment, and discloses a dental plaque quantitative analysis system, a method and a storage medium. The system comprises a dental plaque observation instrument and an upper computer. The dental plaque observation instrument is used for collecting a two-dimensional fluorescence image of teeth in an oral cavity area of a to-be-measured object. The upper computer is in communication connection with the dental plaque observation instrument. The upper computer is configured to: receive the two-dimensional fluorescence image of teeth sent by the dental plaque observation instrument; perform image segmentation and image depth estimation based on the two-dimensional fluorescence image of teeth, perform three-dimensional reconstruction, and obtain a three-dimensional tooth model containing a plaque area and a tooth area; then calculate the surface area of the plaque area and the surface area of the tooth area respectively, obtain an area ratio of the surface area of the plaque area to the surface area of the tooth area, and take the area ratio as a quantitative analysis result of dental plaque. The application can accurately calculate the area of the plaque area and realize high-precision quantitative detection of dental plaque.

This invention belongs to the field of traditional Chinese medicine technology, and discloses a kidney-tonifying and turbidity-resolving traditional Chinese medicine compound, its preparation method, and its anti-atherosclerotic application. The effective components of the kidney-tonifying and turbidity-resolving traditional Chinese medicine compound, by mass, consist of 15 parts Rehmannia glutinosa (processed), 15 parts Astragalus membranaceus (raw), 9 parts Cistanche deserticola, 10 parts Nelumbo nucifera (lotus leaf), 20 parts Gynostemma pentaphyllum, 12 parts Crataegus pinnatifida, and 6 parts Citrus reticulata (dried tangerine peel). The preparation method of the kidney-tonifying and turbidity-resolving traditional Chinese medicine compound is simple, without any additives, and has strong pharmacological compatibility. The anti-atherosclerotic application of the kidney-tonifying and turbidity-resolving traditional Chinese medicine compound includes: including observation cases, grouping, measuring the CIMT value and plaque area of ​​the included cases, data processing, and result analysis. This invention's kidney-tonifying and turbidity-resolving traditional Chinese medicine intervention can reduce the CIMT value and carotid plaque area in patients with atherosclerosis, and has a significant anti-atherosclerotic effect.

The invention provides a city expansion simulation method based on plaque and grid rule multi-scale fusion, and relates to the technical field of geographic information science, and the method comprises the steps: carrying out the classification and numbering of original land utilization data, and carrying out the superposition, and obtaining a city expansion plaque distribution diagram; processing the space factor by using a space analysis tool to obtain driving variable raster data, and further performing plaque averaging processing and sampling on the driving variable raster data to obtain sample data and plaque averaged driving variable raster data; training by using the sample data and the driving variable raster data of plaque averaging, and constructing a plaque potential rule; in the simulation iteration, the simulated land utilization raster data is subjected to matrix processing, and a two-dimensional convolution algorithm is adopted to construct a grid interaction rule; based on the plaque potential rule, the grid interaction rule and the simulation space constraint, the plaque state transition probability is calculated, and the plaque area rule is constructed, so that the city expansion simulation result is determined, and the city expansion simulation precision is effectively improved.

The present invention relates to the use of LAT1 inhibitors in the preparation of drugs for treating atherosclerosis, belonging to the field of pharmaceutical technology. To solve the clinical problem that there is still a relatively high residual risk in advanced atherosclerosis under the current treatment strategies, the present invention provides the use of LAT1 inhibitors in the preparation of drugs for treating atherosclerosis. The present invention has confirmed that LAT1 inhibitors delay the progression of atherosclerosis by inhibiting the entry of leucine into macrophages, reducing plaque area and necrotic core; at the same time, LAT1 inhibitors can also enhance the mitochondrial function of macrophages, increase fatty acid oxidation, reduce lipid deposition in atherosclerotic plaques, increase the stability of atherosclerotic plaques, delay the development of atherosclerosis induced by a high-fat diet, and can be applied to patients in whom the use of other types of anti-atherosclerotic drugs is limited due to diseases such as combined gastrointestinal bleeding, aortic aneurysm or tumor.

The invention relates to application of a reagent for improving MRG15 gene expression in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of biological medicine. Based on the defects that no clear molecular marker for predicting the prognosis of the atherosclerotic patient exists at present and the existing anti-atherosclerotic medicine with the main purpose of lowering lipid cannot improve the prognosis of the patient, in order to improve the treatment effect and the prognosis of the atherosclerotic patient, follow-up visit and sample dyeing are performed on the patient, so that the prognosis of the atherosclerotic patient can be A new atherosclerosis related molecule, namely MRG15, is found, correlation between improvement of MRG15 gene expression and improvement of atherosclerosis is verified, and a new prognosis target is provided for fine management of atherosclerosis patients. In order to ensure the stability of the treatment effect, a specific agonist is screened, and an excellent anti-atherosclerosis effect is achieved. Through in-vivo verification, the plaque area is reduced by 60%-70% after the small molecule medicine litamilast is applied.

A method and apparatus for identifying a vulnerable coronary plaque based on a multimodal large language model (MM-LLM) are provided. The method includes: acquiring a target 3D coronary computed tomography angiography (CCTA) image and a target straightened curved planar reformation (SCPR) image; acquiring plaque mask information of a blood vessel based on the target SCPR image; acquiring basic plaque data based on the plaque mask information; acquiring fluid dynamics data of each plaque area based on the SCPR image; acquiring basic clinical testing information; standardizing above image data, structural data, and textual data separately, and performing, by a regression mapping network, feature fusion to acquire a first fusion feature; acquiring a trained vulnerable plaque identification LLM; and inputting the first fusion feature into the vulnerable plaque identification LLM to acquire an identification result. The method solve problems of poor single-image feature expression ability and low identification performance in traditional technologies.

The invention relates to the technical field of biological medicine, and discloses application of pentadecanoic acid in preparation of a product for treating and / or preventing atherosclerosis, and the molecular formula of the pentadecanoic acid is CH3 (CH2) 13COOH. Experiments show that pentadecanoic acid can significantly reduce the lipid plaque area of an atherosclerosis model mouse, the content of low-density lipoprotein cholesterol in blood and inflammatory response, has good safety and can be used for atherosclerosis treatment.

The invention discloses a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, and relates to the technical field of pharmacy, in particular to a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, the traditional Chinese medicine composition is prepared from the following raw material medicines: 100g of radix puerariae, 100g of herba epimedii, 100g of herba leonuri, 50g of dioscorea panthaica, 50g of raw endothelium corneum gigeriae galli, 50g of fructus aurantii immaturus, 50g of rhizoma dioscoreae nipponicae, 50g of lumbricus and 50g of kapok leaves. Pharmacodynamic tests prove that compared with related traditional Chinese medicine prescriptions in the prior art, the traditional Chinese medicine composition can significantly reduce the intima-media thickness of blood vessels, reduce the area proportion of plaques, improve the blood vessel stenosis rate, and improve the curative effect. 0.05 in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol), protecting vascular endothelial function (increasing the content of vascular endothelial relaxation factor NO and reducing endothelin ET level) and the like, and the pharmaceutical composition is superior to the prior art group (Plt: 0.05) in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride, low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol).

The invention discloses a medicine for treating atherosclerosis caused by high fat diet, and belongs to the technical field of cardiovascular disease treatment. According to the pharmaceutical composition, siRNA (small interfering Ribonucleic Acid) capable of inhibiting expression of LncRNA-ENST00000564510.1 in a targeted manner is used as a core active component, and is combined with a delivery system for use. Animal experiments prove that the siRNA injection medicine can remarkably reduce the aortic plaque area of an atherosclerosis model mouse and effectively improve the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol. Meanwhile, the medicine can remarkably inhibit secretion of vascular endothelial cell inflammatory factors induced by ox-LDL, and the cell activity is improved. Therefore, the invention provides a novel therapeutic drug based on lncRNA targeted regulation, and the novel therapeutic drug has an excellent anti-atherosclerosis effect.